Merck KGaA will expand the reach of its EMD Millipore division with the purchase of life-sciences company Sigma-Aldrich.
Merck KGaA announced on Sept. 22, 2014 that it has agreed to buy Sigma-Aldrich for $140 per share in cash, or a total of $17 billion. The purchase will expand the reach of Merck’s EMD Millipore chemical and equipment division, “increasing the company’s presence in North America and adding exposure to fast-growing Asian markets,” according to a from EMD. Sigma-Aldrich is a life-sciences company that specializes in products used in scientific R&D in fields such as biotechnology, genomics, and pharmaceuticals.
Merck said the transaction will be immediately accretive to Merck KGaA, and Sigma-Aldrich will become part of Millipore. The acquisition is touted to be the largest in Merck's history.
Merck Chairman of the Executive Board Karl-Ludwig Kley said in an interview that with this acquisition, Merck is doubling its business earnings for the academia and lab markets. “Currently we are under-represented in the US and with the strong presence of Sigma-Aldrich in the US market, we’ll have a size which really allows us to take products and service to the customer throughout this great country.”
The transaction is expected to close by mid-2015. Merck expects annual synergies of about €260 million (approximately $333 million), which should be fully achieved within three years after closing, pending regulatory approval.
Source: EMD
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.